Key clinical point: Fludarabine, cyclophosphamide, and rituximab should be first-line therapy for patients with chronic lymphocytic leukemia (CLL) without TP53 disruption.
Major finding: All patients diagnosed with CLL should be tested for TP53 disruption.
Study details: A guideline developed by the British Society for Haematology offering recommendations for CLL treatment outside clinical trials.
Disclosures: The guideline development was supported by the British Society for Haematology. The UK CLL Forum is a registered charity that receives funding from a number of pharmaceutical companies.
Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460.
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in CLL
Uninterrupted ibrutinib with CAR T may boost outcomes in CLL , Gauthier J et al. ASH 2018, Abstract 299
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018
Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
First-line ibrutinib has long-term survival benefit, Barr PM et al. Haematologica. 2018;103(9):1502-10.